Clinical Trial Update: Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma [Phase 1]

View source ↗

Summary

Phase 1 trial from MD Anderson evaluating genetically modified T-cells followed by Aldesleukin in patients with stage III to IV melanoma. The study is currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Aldesleukin (interleukin-2)
• Genetically Modified T Cells

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7 | Phase 1 | Status: ACTIVE_NOT_RECRUITING